Shiraishi Takuya, Ogawa Hiroomi, Katayama Ayaka, Osone Katsuya, Okada Takuhisa, Enokida Yasuaki, Oyama Tetsunari, Sohda Makoto, Shirabe Ken, Saeki Hiroshi
Department of General Surgical Science Gunma University Graduate School of Medicine Maebashi Japan.
Department of Diagnostic Pathology Gunma University Graduate School of Medicine Maebashi Japan.
Ann Gastroenterol Surg. 2022 Mar 21;6(5):667-678. doi: 10.1002/ags3.12571. eCollection 2022 Sep.
Tumor size in pathological T4 (pT4) colorectal cancer (CRC) is associated with oncological prognosis; however, its relation to epithelial-mesenchymal transition (EMT)-associated histology is unclear. We aimed to investigate the association of tumor size with oncological prognosis and EMT.
We performed a retrospective analysis of 95 patients with primary CRC who underwent radical surgery and were consecutively diagnosed with pT4.
Both 3-y disease-free survival (DFS) and cancer-specific survival (CSS) were significantly higher in patients with tumor size ≥50 mm than in those with tumor size <50 mm ( = .009 and = .011, respectively). The independent factors identified in the multivariate analysis for DFS were pathological lymph node metastasis (hazard ratio [HR], 2.551; 95% confidence interval [CI], 1.031-6.315; = .043), distant metastasis (HR, 2.511; 95% CI, 1.140-5.532; = .022), tumor size (HR, 0.462; 95% CI, 0.234-0.913; = .026), and adjuvant chemotherapy (HR, 0.357; 95% CI, 0.166-0.766; = .008). The independent factors identified in multivariate analysis for CSS were tumor location (HR, 10.867; 95% CI, 2.539-45.518; = .001) and tumor size (HR, 0.067; 95% CI, 0.014-0.321; < .001). In pT4 CRC, smaller tumor size was associated with nonmature desmoplastic reaction and EMT-related histology.
Tumor size ≥50 mm was associated with a better DFS and CSS than that of <50 mm, in patients with pT4 CRC. Smaller tumor size with advanced invasion likely reflects a more biologically aggressive phenotype in pT4 CRC.
病理T4(pT4)期结直肠癌(CRC)的肿瘤大小与肿瘤学预后相关;然而,其与上皮-间质转化(EMT)相关组织学的关系尚不清楚。我们旨在研究肿瘤大小与肿瘤学预后及EMT的相关性。
我们对95例行根治性手术且连续诊断为pT4的原发性CRC患者进行了回顾性分析。
肿瘤大小≥50 mm的患者3年无病生存率(DFS)和癌症特异性生存率(CSS)均显著高于肿瘤大小<50 mm的患者(分别为P = 0.009和P = 0.011)。多因素分析确定的DFS独立因素为病理淋巴结转移(风险比[HR],2.551;95%置信区间[CI],1.031 - 6.315;P = 0.043)、远处转移(HR,2.511;95% CI,1.140 - 5.532;P = 0.022)、肿瘤大小(HR,0.462;95% CI,0.234 - 0.913;P = 0.026)和辅助化疗(HR,0.357;95% CI,0.166 - 0.766;P = 0.008)。多因素分析确定的CSS独立因素为肿瘤位置(HR,10.867;95% CI,2.539 - 45.518;P = 0.001)和肿瘤大小(HR,0.067;95% CI,0.014 - 0.321;P < 0.001)。在pT4 CRC中,较小的肿瘤大小与未成熟的促纤维组织增生反应和EMT相关组织学有关。
在pT4 CRC患者中,肿瘤大小≥50 mm的患者DFS和CSS优于肿瘤大小<50 mm的患者。侵袭性较强但肿瘤较小可能反映了pT4 CRC中更具生物学侵袭性的表型。